Background. The aim of our study was to assess the detection of circulating DNA from the most common species of Mucorales for early diagnosis of mucormycosis in at-risk patients.
malignancy [3] . Mucormycosis is being diagnosed more and more frequently in developing countries, especially in India, China, and Latin America [4, 5] . Rhino-orbitocerebral presentation is the predominant form, possibly because of its association with diabetes. Renal mucormycosis has also emerged as a new clinical entity in India and China [6] .
Rhizopus species are the most common genera in the United States and in France (55% and 49%, respectively). Distribution of other Mucorales species depends on geographical location. Rhizopus species were followed by Mucor species (19%), Rhizomucor species (7%), Cunninghamella species (9%), and Lichtheimia species (formerly Absidia species, 3%) in the United States, and by Lichtheimia species (29%), Rhizomucor species (7%), and Mucor species (3%) in France [7] . The prognosis of mucormycosis remains poor, with a reported mortality rate between 22% and 25% for cutaneous and rhinocerebral infections, to between 48% and 79% for pulmonary and disseminated forms [7] .
Clinically and radiographically, mucormycosis is often indistinguishable from other invasive mold infections such as aspergillosis and remains difficult to diagnose. Coinfection with Aspergillus species may be frequent [3] . However, Mucorales species are not susceptible to voriconazole, which is often used as a first-line treatment in aspergillosis. Thus, early specific diagnosis and prompt therapeutic intervention with active antifungal treatment such as amphotericin B are essential for improving the outcome of mucormycosis.
Diagnosis is done by histopathological examination and positive culture of a Mucorales species. Mucorales polymerase chain reaction (PCR) performed on formalin-fixed, paraffinembedded tissue samples followed by sequencing is useful for diagnosis confirmation in cases of culture-negative invasive mold infection [8, 9] . However, in a clinical setting, obtaining deep tissue samples or bronchoalveolar lavage fluids from a patient with suspected mucormycosis may be not feasible, especially in hematological patients. If done, histopathological identification of Mucorales in tissue specimens is difficult and requires significant expertise. Moreover, Mucorales species observed in tissue often fail to grow in fungal culture [8] . Up to now, none of the fungal biomarkers available (β-glucan, galactomannan) have been useful for mucormycosis diagnosis. Developing DNA or antigen-based detection for early diagnosis has been underlined as a key issue in mucormycosis research [10] .
Circulating DNA from Mucorales has been detected in plasma samples obtained from an in vivo rabbit model of invasive pulmonary mucormycosis. Specific DNA was detected using quantitative PCR in plasma samples from rabbits infected with Rhizopus, Mucor, and Cunninghamella species, as early as day 1 after inoculation [11] . A molecular approach, detecting circulating DNA from Mucorales in at-risk patients, may thus help to diagnose invasive mucormycosis quickly and to introduce directed therapy earlier.
The aim of our study was to assess the detection of circulating DNA from the most common species of Mucorales for early diagnosis of mucormycosis in at-risk patients. We retrospectively evaluated a combination of 3 quantitative PCR (qPCR) assays targeting Mucor/Rhizopus, Lichtheimia, and Rhizomucor species using serial serum samples from 10 patients diagnosed with proven mucormycosis between January 2004 and June 2012 in our hospital.
MATERIALS AND METHODS

Strains
Nineteen strains from the fungal species that are most frequently isolated in human infections, either from an international collection ( Fungal DNA was extracted using the High Pure PCR Template Preparation Kit (Roche Diagnostics, Meylan, France), according to the manufacturer's recommendations, after the mechanical disruption of mycelia in liquid nitrogen using a pestle for molds. DNA extract from Mucorales species was serially diluted from 300 femtograms [fg]/10 µL to 1 fg/10 µL for qPCR sensitivity testing. For all other species, DNA concentrations were adjusted to 300 fg/10 µL for qPCR specificity testing. For each qPCR assay, a positive control containing 30 fg/10 µL of DNA from the main targeted species was prepared. These controls were run in 10 separate series to assess reproducibility.
Patients
Twenty-one patients were diagnosed with proven or probable mucormycosis at the University Hospital of Besançon between January 2004 and June 2012. Ten patients diagnosed with proven mucormycosis and with available sera at the time of diagnosis were included in the study. The date of histopathological diagnosis was defined as day 0. Other patients presenting with probable mucormycosis, or without available sera between day -10 and day 10 were not included. Biological, radiological, and clinical data were collected at the time of diagnosis. Seven patients had hematological malignancy: acute myeloid leukemia (AML; n = 2), lymphoma (n = 2), acute lymphoid leukemia (n = 1), allogenic hematopoietic stem cell transplant (allo-HSCT) for myelodysplasia (n = 1), severe aplastic anemia (n = 1); and 3 patients had other risk factors (renal transplantation, polytraumatism, alcoholism, and undernutrition).
The clinical presentations included pulmonary (n = 1), rhinocerebral (n = 2), cutaneous (n = 1), and disseminated (n = 6) localizations. All the cases were proven mucormycosis according to European Organization for Research on Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) consensual definitions (Table 1) , with identification of causative Mucorales by culture and/or molecular techniques on biopsies. Positive culture was obtained in 7 patients: Lichtheimia c. (n = 3), L. ramosa (n = 1), R. pusillus (n = 2), and R. oryzae (n = 1). In 7 of 10 cases, fresh and/or paraffin-embedded tissues were available for investigation by PCR sequencing targeting 18S ribosomal DNA (18S rDNA), as described by Bialek et al [12] , and/or internal transcribed spacer [13] . For the 3 patients without positive culture, the causative Mucorales species was identified using molecular techniques only: it was Lichtheimia species for patient 4, R. oryzae for patient 7, and Rhizomucor species for patient 10.
Negative Controls
Ten healthy patients without hematological malignancy and 10 patients with hematological malignancy but without invasive fungal infection described in a previous study [14] were included as negative controls. Sera from 17 patients with probable or proven invasive aspergillosis according to EORTC/ MSG criteria [15] and sera from 14 patients with Pneumocystis jirovecii infection were tested using the 3 qPCR assays.
Quantitative PCR Assays
The following 3 qPCR assays, previously described by the US Environmental Protection Agency for environmental analysis, were adapted for detection of Mucorales DNA from serum: (1) Absidia corymbifera (assay name: Acory [qPCR assay was designed before the taxonomy was changed from Absidia to Lichtheimia]); (2) Mucor amphibiorum/circinelloides/hiemalis/ indicus/mucedo/racemosus/ramosissimus and Rhizopus azygosporus/homothalicus/microsporus/oligosporus/oryzae (assay name: Muc1); (3) Rhizomucor meihei/pusillus/variabilis (assay name: Rmuc).
Sequences from primers and probes can be found on the US Environmental Protection Agency website (http://www. epa.gov/nerlcwww/moldtech.htm#primers).
The PCR mix was prepared in a 20 µL final volume using the LightCycler 480 Probes Master (Roche Diagnostics, Meylan, France): 11 µL of Master Mix containing 0.4 µL probe (P1, 4 µM), 0.5 µL primers (F1/R1, 40 µM), and 9 µL DNA. PCR reactions were run on a LightCycler 480 Instrument II (Roche Diagnostics). The thermal cycling conditions were as follows: an initial denaturation step at 95°C for 10 minutes, followed by 50 cycles of 15 seconds at 95°C, and 1 minute at 60°C. We did not use an internal control for inhibition because with the type of commercial kit we used, PCR inhibitors are rarely observed [16] .
Detection of Circulating DNA in Serum Detection of fungal DNA using qPCR was done retrospectively on 51 serum samples stored at −20°C. Sera sampled between day -75 and day 29 from the time of diagnosis of mucormycosis were tested (2-9 sera per patient).
Automatic DNA extraction was performed using 1 mL of serum with a Large Volume MagNa Pure Nucleic Acid Isolation Kit on a MagNa Pure Compact apparatus (Roche Diagnostics, Meylan, France). Elution was performed in a 50-µL volume. Detection of fungal DNA was performed with 9 µL of extract, using each of the 3 qPCR assays described above.
Quantitative results were expressed by determining the detection threshold, or quantification cycle (Cq), that marked the cycle at which fluorescence of the sample became significantly different from the baseline signal. Thus, the higher the Cq, the smaller the amount of DNA in the sample.
RESULTS
Cross-Reactivity, Reproducibility, and Detection Limits of PCR
Amplification was obtained only with DNA extracts from the targeted species for each of the 3 qPCR assays: L. corymbifera, L. ramosa, L. ornata with the Acory assay; R. oryzae, M. racemosus, and M. ramosissimus with the Muc1 assay; and R. pusillus with the Rmuc assay. No cross-reactivity with other DNA fungal extracts was detected for any of the 3 qPCR assays. Serial dilution of DNA extracts showed that the limit of detection ranged from 3.7 to 15 fg/10 µL depending on the species (Table 2) . Reproducibility testing showed that the variation coefficient was <0.02 (mean Cq ± 1) for each of the qPCR assays.
Detection of Circulating DNA in Serum
All of the 3 qPCR assays were negative in patients without hematological malignancy and in patients with hematological malignancy but without invasive fungal infection. All 3 qPCR assays were also negative in sera from patients with invasive aspergillosis and Pneumocystis infection. Quantitative PCR was negative in only 1 patient ( patient 1) with proven disseminated mucormycosis, caused by L. corymbifera. The combination of 3 targeted qPCR assays was positive before diagnosis for the 9 other patients with proven mucormycosis. All the positive qPCR results were concordant with culture and/or PCR-based identification of the causing agents in tissue (Lichtheimia, Rhizomucor, and Mucor/Rhizopus qPCR assay positive in 4, 3, and 2 patients, respectively). First serum with positive qPCR was sampled from 68 to 3 days before diagnosis, with Cq between 39 and 25 cycles (Table 1 ). In 5 of the 9 patients, circulating Mucorales DNA was detected 1-8 days before occurrence of the first clinical or radiological signs. Of note, 2 patients showed circulating DNA >6 weeks before diagnosis of proven mucormycosis (68 and 49 days, respectively).
Patient 7 presented with circulating Rhizopus DNA at day -68. She was originally diagnosed with probable pulmonary aspergillosis (nodules, halo sign, positive galactomannan in serum at day -62) during induction chemotherapy for AML. She received a combination of liposomal amphotericin B (L-AmB) 3 mg/kg/day and voriconazole for 14 days (day -61 to day -49), followed by combined voriconazole-caspofungin (day -48 to day -23), and later voriconazole-L-AmB (day -22 to day -5), voriconazole-caspofungin (day -4 to day 31), and voriconazole-L-AmB (day 32 to day 98, including allo-HSCT at day 50). Lobectomy was planned before allo-HSCT. Diagnosis of proven aspergillosis was performed by examination of lung operative specimen (day 0: positive histology, negative mycological culture). The diagnosis of AspergillusMucorales coinfection was performed retrospectively 3 years later by another expert pathologist examination (2 distinct types of hyphae, including characteristic features of Mucorales hyphae) and molecular analysis of day 0 operative specimens.
Rhizomucor DNA was detectable at day -49 in patient 10, who presented with febrile neutropenia associated with pulmonary nodules during induction chemotherapy of AML. Initial antifungal therapy based on intravenous voriconazole was switched to L-AmB (day -44 to day -35), because voriconazole caused neurological adverse events to occur rapidly. The patient was discharged from hospital at day -35, with posaconazole therapy. Compliance to posaconazole therapy remained poor, however. Radiological evidence of liver and spleen abscesses (day -7) led to surgical resection and then diagnosis by direct examination of operative specimens (liver and spleen abscesses, day 0), confirmed by histology and molecular analysis performed on these specimens.
Only 4 patients underwent surgery ( pulmonary lobectomy in patient 7, abdominal surgery in 2 patients ( patients 5 and 10), and sinus debridement without enucleation in patient 8). All 4 of these patients were alive at day 90 after diagnosis, while the 6 patients who were not treated with surgery died before day 15 (5/6 patients died before day 3).
DISCUSSION
Detection of specific circulating DNA appears to be a noninvasive, sensitive, and specific technique that may be a useful tool for early diagnosis of infection involving Mucorales, especially in patients who cannot undergo a biopsy or a bronchoalveolar lavage due to thrombocytopenia, coagulopathy, or any other reason. We were able to detect Mucorales DNA in serum samples from 9 of 10 patients up to 68 days before mucormycosis diagnosis was confirmed by histopathological examination and/or positive culture. The combination of 3 targeted qPCR assays allowed us to diagnose the genera implicated accurately, and in particular could identify the L. corymbifera species, which is the most frequent cause of mucormycosis in our hospital (8/21 cases of proven or probable mucormycosis diagnosed between January 2004 and June 2012). Specificity of the 3 qPCR assays was checked: no cross-amplification with yeast species or other molds commonly causing invasive fungal infection (Fusarium, Scedosporium, and Aspergillus species) was observed. This very good specificity is the main advantage of the technique, especially in cases of double infections that are difficult to diagnose by histopathological examination. Indeed, infections with a concomitant fungal pathogen were observed in one-third of patients (8/24) with mucormycosis in one well-described series, including Aspergillus, Fusarium, or Candida coinfection [17] . Occurrence of such coinfections is probably underreported [9] . However, detection of double infections involving a Mucorales species is crucial for identifying an appropriate treatment. Detecting Mucorales circulating DNA, in association with the detection of other biomarkers (β-glucan, galactomannan, and Aspergillus circulating DNA), could be very helpful when making the decision to initiate directed therapy early in patients showing radiological signs of fungal infection. Patient 7 is a good example of this kind of coinfection, as she showed numerous positive galactomannanemia and positive Aspergillus qPCR, concomitantly with positive Mucorales DNA detection in sera.
We used primers and probes that targeted the 18S rDNA gene to detect circulating DNA from the most common species causing mucormycosis in Europe (Mucor/Rhizopus species, Lichtheimia species, and Rhizomucor species); targeting this multicopy gene allows us to detect a very small amount of DNA. Indeed, in our preliminary experiment, as few as 3.7-15 fg DNA could be detected, depending on the species and target studied. These values were quite similar to those we obtained previously (3 fg) with Aspergillus qPCR [14] . The copy numbers of the 18S rDNA varied between fungal species [18] , and also between different strains of the same species, that is, Aspergillus fumigatus with 38-91 copies per genome [19] . Quantification of rDNA provided by qPCR and qPCR assay limit of detection depend on infecting species or strains, as the 18S rDNA copy number cannot be assumed based on another value previously determined from an unrelated strain.
The ability to detect a very small amount of DNA is essential for early diagnosis using qPCR techniques. There are numerous benefits of early mucormycosis diagnosis: prevention of progression to dissemination, reduced need for surgery or less surgical resection, less disfigurement and suffering, and improvement of outcome and survival [20] . Delayed therapy was shown to result in a 2-fold increase in mortality at 12 weeks [21] . In our series, 6 of the 10 patients died before day 90, including 3 patients without any Mucorales-active antifungal treatment, and 3 patients who died 1-15 days after implementation of L-AmB therapy. For all patients except 1 with a negative PCR result, appropriate antifungal treatment would have been given between 1 and 23 days earlier and/or not temporarily discontinued (as in patient 7) if the PCR result had been known.
Taxonomy of the L. corymbifera complex was recently reevaluated and 3 distinct species are now recognized: L. corymbifera, L. ramosa, and L. ornata [22, 23] . Interestingly, the qPCR Acory assay is able to detect all 3 species. The L. corymbifera "complex" is a rare cause of mucormycosis in the United States [1] but has been reported as one of the main species identified in France (29%) [7] , and accounted for 19% of species in a recent European series [24] . Lichtheimia species were identified in 38% of cases of probable and proven invasive mucormycosis since 2004 in our hospital, and were observed in 50% of the patients in this study. Environmental differences probably explain these contrasting data. Besançon is located in a rural area in eastern France, where the L. corymbifera complex has been shown to be one of the most frequent molds in farming environments and an etiological agent of farmer's lung disease [25] . Four of the 5 patients with mucormycosis due to Lichtheimia species in our series had been living in a rural district (ie, villages with <2000 inhabitants).
Our strategy does not include a pan-Mucorales DNA assay or a specific qPCR assay targeting less frequent genera of Mucorales (ie, Cunninghamella species, Saksenaea species, Apophysomyces species), contrary to previous qPCR studies [11, 26] , but infections due to such fungi have never been diagnosed in our institution. Specific qPCR assays targeting these genera should be implemented to optimize the panel of species detected, if required by local ecology. Detection of additional Mucorales species from subtropical areas could be required in assays to be used in developing countries.
Our study suggests that using specific qPCR targeting several species of Mucorales according to local ecology for screening at-risk patients is feasible in a clinical setting. Indeed, the use of a high-throughput qPCR system reduces analysis time and cost. About a hundred samples can be analyzed with different targets in a single run of 2 hours, if harmonized amplification protocols are used. A key issue will be to identify the population of susceptible patients to increase the positive predictive value of the assay result [11] . First, the combination of the 3 qPCR assays targeting Mucorales species is now performed in our hospital in immunocompromised patients with clinical signs of fungal infection, when available biomarkers (galactomannan, β-glucan and qPCR targeting Aspergillus species) remain negative. Second, a strategy including a combination of the 3 qPCR assays targeting Mucorales species and 2 qPCR assays targeting Aspergillus species for twice-weekly screening of very high-risk patients ( patients with acute leukemia or lymphoma receiving intensive chemotherapy, during the aplasia period, and allo-HSCT recipients, from day 0 to day 35 after the graft) is ongoing for prospective evaluation. The cost and efficacy of this strategy should be evaluated. However, given the human and economic cost of mucormycosis, the importance of rapid diagnosis to initiate a prompt, efficient antifungal therapy, and the possible cost optimization of a high-throughput qPCR system, we believe this strategy could be highly attractive.
Notes
